Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients.
In order to evaluate the efficacy of interferon alpha (IFNa) in mixed cryoglobulinemia (MC), a prospective multicenter clinical trial was conduced in April 1992. It consisted of treating 20 clinically symptomatic MC patients with IFNa for 26 weeks. Hepatitis C virus (HCV) infection was detected in 16 patients. A complete or partial clinical remission was obtained in 12 patients (60%). Eleven of these 12 responders (91.6%) experienced a clinical relapse less than 12 months after the end of therapy. Side effects were noted in 10 patients (50%). It was concluded that subcutaneously administered IFNa does not provide long-term remission.
Cohen
P
P
Service de Médecine Interne. Hôpital Avicenne, Université Paris-Nord, Bobigny, France.
Nguyen
Q T
QT
Dény
P
P
Ferrière
F
F
Roulot
D
D
Lortholary
O
O
Jarrousse
B
B
Danon
F
F
Barrier
J H
JH
Ceccaldi
J
J
Constans
J
J
Crickx
B
B
Fiessinger
J N
JN
Hachulla
E
E
Jaccard
A
A
Seligmann
M
M
Kazatchkine
M
M
Laroche
L
L
Subra
J F
JF
Turlure
P
P
Guillevin
L
L
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003449:Cryoglobulinemia / Q000150:complications / Q000628:therapy*; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000628:therapy; D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D011446:Prospective Studies; D011994:Recombinant Proteins; D012008:Recurrence
D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins